ArticleArteriosclerosis, thrombosis, and vascular biology2016
Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Levels of Prebeta-1 High-Density Lipoprotein Are a Strong Independent Positive Risk Factor for Coronary Heart Disease and Myocardial Infarction: A Meta-Analysis.Journal of the American Heart Association · 2021Pooled it
- Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients.British journal of clinical pharmacology · 2021Trial
- Effects of Replacing Dietary Monounsaturated Fat With Carbohydrate on HDL (High-Density Lipoprotein) Protein Metabolism and Proteome Composition in Humans.Arteriosclerosis, thrombosis, and vascular biology · 2019Trial
- Dietary unsaturated fat increases HDL metabolic pathways involving apoE favorable to reverse cholesterol transport.JCI insight · 2019Trial
- Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.JCI insight · 2018Trial
- Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients.Scientific reports · 2017Trial
- Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia.Journal of lipid research · 2016Trial
- Sex steroids mediate discrete effects on HDL cholesterol efflux capacity and particle concentration in healthy men.Journal of clinical lipidologyTrial
- ABCA1-Mediated Structural Diversity of HDL Subspecies and Their Proposed Roles in Cardioprotection.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels.American journal of preventive cardiology · 2025Review
- Distinct roles of size-defined HDL subpopulations in cardiovascular disease.Current opinion in lipidology · 2025Review
- Relationship of high-density lipoprotein subfractions and apolipoprotein A-I with fat in the pancreas.Diabetes, obesity & metabolism · 2025Article
- Understanding HDL Metabolism and Biology Through In Vivo Tracer Kinetics.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- The distinct metabolism between large and small HDL indicates unique origins of human apolipoprotein A4.JCI insight · 2023Article
- High-density lipoprotein revisited: biological functions and clinical relevance.European heart journal · 2023Review
- The Impact of Aerobic Exercise on HDL Quantity and Quality: A Narrative Review.International journal of molecular sciences · 2023Review
- Changes in the size and electrophoretic mobility of HDL subpopulation particles in chronic kidney disease.Journal of nephrology · 2023Article
- The dawn of a new era of targeted lipid-lowering therapies.European heart journal · 2022Review
- Different Pathways of Cellular Cholesterol Efflux.Cell biochemistry and biophysics · 2022Review
- Metabolism of PLTP, CETP, and LCAT on multiple HDL sizes using the Orbitrap Fusion Lumos.JCI insight · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
objectiveA prevailing concept is that high-density lipoprotein (HDL) is secreted into the systemic circulation as a small mainly discoidal particle, which expands progressively and becomes spherical by uptake and esterification of cellular cholesterol and then contracts by cholesterol ester delivery to the liver, a process known as reverse cholesterol transport, thought to be impaired in people with low HDL cholesterol (HDLc). This metabolic framework has not been established in humans. APPROACH AND
resultsWe studied the metabolism of apolipoprotein A-I in 4 standard HDL sizes by endogenous isotopic labeling in 6 overweight adults with low HDLc and in 6 adults with normal body weight with high plasma HDLc. Contrary to expectation, HDL was secreted into the circulation in its entire size distribution from very small to very large similarly in both groups. Very small (prebeta) HDL comprised only 8% of total apolipoprotein A-I secretion. Each HDL subfraction circulated mostly within its secreted size range for 1 to 4 days and then was cleared. Enlargement of very small and medium to large and very large HDL and generation of very small from medium HDL were minor metabolic pathways. Prebeta HDL was cleared slower, whereas medium, large, and very large HDL were cleared faster in the low HDLc group.
conclusionsA new model is proposed from these results in which HDL is metabolized in plasma mainly within several discrete, stable sizes across the common range of HDLc concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.